Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension

Advances in Therapy

Volumn 24, Issue 2, 2007, Pages 302-309

  Mundorf, Thomas ^a   Noecker, Robert J ^b,d   Earl, Melissa ^c  

^a Eye and Ear Institute ^*

^b University of Pittsburgh School of Medicine   (United States)

^c UPMC Eye Center   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Alphagan P; Brimonidine; Glaucoma; Latanoprost; Xalatan

Indexed keywords

ALPHAGAN P; BRIMONIDINE; BRIMONIDINE PURITE; DORZOLAMIDE; LATANOPROST; TIMOLOL; UNCLASSIFIED DRUG;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EYE ALLERGY; FEMALE; FOREIGN BODY REACTION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; QUINOXALINES;

EID: 34250862037     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849898     Document Type: Article

References (17)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389-393.
2. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122:532-538.
3. Research to Prevent Blindness. Glaucoma. Available at: http://www.rpbusa.org/glaucoma.php. Accessed August 8, 2006.
4. Lichter PR, Musch DC, Gillespie BW, et al for the CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943-1953.
5. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
6. Allergan, Incorporated. Alphagan® P prescribing information. Available at: http://www.allergan.com/download/ALPHGANP_PI.pdf. Accessed August 7, 2006.
7. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119-126.
8. Simmons ST, Earl ML, for the Alphagan/Xalatan Study Group. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology. 2002;109:307-315.
9. Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma. 2001;10:220-226.
10. Zabriskie NA, Ahmed IK, Cantor LB, et al. Safety and efficacy of combination therapy with brimonidine 0.2% and latanoprost 0.005% versus fixed timolol 0.5%/dorzolamide 2% in patients with glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41(suppl 4):S833.
11. Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Clin Ther. 2000;22:103-111.
12. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997;115:847-852.
13. Leske ME, Heijl A, Hussein M, et al, for the Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48-56.
14. Allergan, Inc. Alphagan® P FAQs. Available at: http://www.alphaganp. com/ALPHGANP.pdf. Accessed August 7, 2006.
15. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-1304.
16. Goldberg I. Drugs for glaucoma. Aust Prescr. 2002;25:142-146.
17. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128:8-14.